CLOs on the Move

Putnam Science

www.putnamscience.org

 
Putnam Science is a Putnam, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million

Executives

Name Title Contact Details

Similar Companies

Infusion Associates

Infusion Associates is a physician practice that specializes in IV infusions and injections. They provide medically prescribed infusions for patients with chronic disease in a comfortable, outpatient environment instead of a hospital.

LifeBrands

LifeBrands is a New York, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Calimmune

Calimmune, Inc., a clinical-stage human immunodeficiency virus (HIV) gene medicines company, develops cell-based therapies for HIV. The company offers Cal-1, a gene-based stem cell therapy to protect individuals infected with HIV from progressing to AIDS. It also focuses on developing products to address the needs of various types of individuals at different states of HIV infection and with different levels of treatment experience..

Adolescent AIDS Program

Adolescent AIDS Program is a Hastings, NE-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Neurotrope Inc

Neurotrope was formed in October 2012 to develop and market two product platforms, including a non-invasive diagnostic test for Alzheimer's Disease and a drug candidate called bryostatin for the treatment of Alzheimer's Disease, both of which are in the clinical testing stage.  Neurotrope was formed for the primary purpose of commercializing certain technologies that were initially developed by Blanchette Rockefeller Neurosciences Institute ("BRNI") and its affiliates, for therapeutic or diagnostic applications for Alzheimer's Disease or other cognitive dysfunctions.  These technologies have been under development since 1999 and have been financed through significant funding from a variety of non-investor sources. The Company expects that its first product, the diagnostic test for Alzheimer's Disease, will finish the testing phase of its development in 2015, whereupon the Company will evaluate the feasibility of its commercialization.  In addition to bryostatin and the diagnostic test for Alzheimer's Disease, the Company intends to pursue development of two other technology platforms developed by and licensed from BRNI: the first, a platform for transporting drugs into the brain through the "blood-brain-barrier," and the second, a group of drugs for enhancing cognition, mood and alertness for neuropsychiatric conditions.